Context Therapeutics Inc. cotiza a 0.28 USD y tiene una capitalización bursátil de $25M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.15 | $-0.09 | $-0.14 | $-0.10 |
| Estimado | $-0.09 | $-0.12 | $-0.11 | $-0.09 |
| Sorpresa | -66.7% | +25.0% | -27.3% | -11.1% |
| Métrica | CNTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -59.7% | -40.4% | -19.3% |
| ROA | -52.7% | -32.0% | -20.7% |
| Current Ratio | 8.52 | 2.84 | +5.68 |
| Debt / Equity | — | 0.28 | — |